Stockreport

Bavarian Nordic Completes Enrollment of First Stage in Chordoma Phase 2 Trial

BAVARIAN NORDIC R/I S/ADR  (BVNRY) 
NASDAQ:AMEX Investor Relations: bavarian-nordic.com/investor.aspx
PDF COPENHAGEN, Denmark, January 25, 2019 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today, that the first stage of a Phase 2 study of its novel, targeted cance [Read more]